Bmp potentiators

Abstract

Also provided are methods of making the compounds of Formula (I) and their methods of use.

1 . A method of potentiating bone morphogenetic protein (BMP) signaling in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: 
       
         
           
           
               
               
           
         
         each R 1  is independently selected from the group consisting of halo, cyano, C 1-6  alkyl, C 1-6  alkoxyl, C 2-6  alkenyl, C 2-6  alkynyl, heteroC 1-10  alkyl, and C 1-6  haloalkyl; 
         n is 1, 2, 3, 4, or 5; and 
         m is 0, 1, 2, 3, or 4. 
       
     
     
         2 . The method of  claim 1 , wherein n is 1, 2 or 3. 
     
     
         3 . The method of  claim 1 , wherein n is 1. 
     
     
         4 . The method of  claim 1 , wherein R 1  is selected from the group consisting of halo and C 1-6  alkyl. 
     
     
         5 . The method of  claim 1 , wherein m is 0 or 1. 
     
     
         6 . The method of  claim 1 , wherein m is 0. 
     
     
         7 . The method of  claim 1 , wherein the compound is compound (A): 
       
         
           
           
               
               
           
         
       
     
     
         8 . A method of treating a disease or disorder in a subject in need thereof selected from the group consisting of: PAH (pulmonary arteria hypertension); HHT (hereditary hemorrhagic telangiectasia); iron overload anemia; fracture healing; macular degeneration; glaucoma; dry eye; colitis; IBD (inflammatory bowel disease); juvenile polyposis syndrome; and fibrosis, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: 
       
         
           
           
               
               
           
         
         each R 1  is independently selected from the group consisting of halo, cyano, C 1-6  alkyl, C 1-6  alkoxyl, C 2-6  alkenyl, C 2-6  alkynyl, heteroC 1-10  alkyl, and C 1-6  haloalkyl; 
         n is 1, 2, 3, 4, or 5; and 
         m is 0, 1, 2, 3, or 4. 
       
     
     
         9 . The method of  claim 8 , wherein n is 1, 2 or 3. 
     
     
         10 . The method of  claim 8 , wherein n is 1. 
     
     
         11 . The method of  claim 8 , wherein R 1  is selected from the group consisting of halo and C 1-6  alkyl. 
     
     
         12 . The method of  claim 8 , wherein m is 0 or 1. 
     
     
         13 . The method of  claim 8 , wherein m is 0. 
     
     
         14 . The method of  claim 8 , wherein the compound is compound (A): 
       
         
           
           
               
               
           
         
       
     
     
         15 . The method of  claim 8 , wherein the macular degeneration is AMD (age-related macular degeneration). 
     
     
         16 . The method of  claim 8 , wherein the fibrosis is selected from lung, liver and kidney.